Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent
- 308 Downloads
Angiogenesis plays a pivotal role in tumorigenesis and also contributes to the pathogenesis of hematologic malignancies. A number of plant compounds have shown efficacy in preclinical and clinical studies and some of them possess an anti-angiogenic activity. Our present findings report anti-angiogenic activities of ethoxyfagaronine (etxfag), a synthetic derivative of fagaronine. Once determined the non-cytotoxic concentration of etxfag, we showed that the drug inhibits VEGF-induced angiogenesis in a Matrigel™ plug assay and suppresses ex vivo sprouting from VEGF-treated aortic rings. Each feature leading to neovascularization was then investigated and results demonstrate that etxfag prevents VEGF-induced migration and tube formation in human umbilical vein endothelial cells (HUVEC). Moreover, etxfag also suppresses VEGF-induced VEGFR-2 phosphorylation and inhibits FAK phosphorylation at Y-861 as well as focal adhesion complex turnover. Beside these effects, etxfag modifies MT1-MMP localization at the endothelial cell membrane. Finally, immunoprecipitation assay revealed that etxfag decreases VEGF binding to VEGFR-2. As we previously reported that etxfag is able to prevent leukemic cell invasiveness and adhesion to fibronectin, all together our data collectively support the anti-angiogenic activities of etxfag which could represent an additional approach to current anti-cancer therapies.
KeywordsEthoxyfagaronine Angiogenesis VEGF receptor FAK MT1-MMP
Plateforme IBiSA PICT “Imagerie Cellulaire et Tissulaire” This work was supported by grants from CNRS and Ligue Contre le Cancer Grand Est. We would like to thank J.L. Breda for animal care. The authors acknowledge Dr Laetitia Devy Dimanche for editorial assistance.
Conflict of interest
The authors declare that they have no conflict of interest.
- 15.Lynch MA, Duval O, Sukhanova A, Devy J, MacKay SP, Waigh RD et al (2001) Synthesis, biological activity and comparative analysis of DNA binding affinities and human DNA topoisomerase I inhibitory activities of novel 12-alkoxy-benzo[c]phenanthridinium salts. Bioorg Med Chem Lett 11:2643–2646PubMedCrossRefGoogle Scholar
- 16.Deroussent A, Re M, Hoellinger H, Vanquelef E, Duval O, Sonnier M et al (2004) In vitro metabolism of ethoxidine by human CYP1A1 and rat microsomes: identification of metabolites by high-performance liquid chromatography combined with electrospray tandem mass spectrometry and accurate mass measurements by time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 18:474–482PubMedCrossRefGoogle Scholar
- 19.Abu-Ghazaleh R, Kabir J, Jia H, Lobo M, Zachary I (2001) Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. Biochem J 360:255–264PubMedCentralPubMedCrossRefGoogle Scholar
- 24.Thevenard J, Ramont L, Devy J, Brassart B, Dupont-Deshorgue A, Floquet N et al (2010) The YSNSG cyclopeptide derived from tumstatin inhibits tumor angiogenesis by down-regulating endothelial cell migration. Int J Cancer J Int Du Cancer 126:1055–1066Google Scholar
- 30.Devy J, Ouchani F, Oudot C, Helesbeux JJ, Vanquelef E, Salesse S, et al (2010). The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity. Invest New DrugsGoogle Scholar